drugset / Trial / NCT06448026

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma

NCT06448026

NaSingle-groupOpen-labelTreatment

Summary

To learn if giving cemiplimab and cetuximab before salvage surgery can help to control recurrent oral cavity squamous cell carcinoma.

Timeline

Start
2024-11-21
Primary completion
2027-05-15
Completion
2027-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Cemiplimab Monoclonal antibody Intravenous
Subject Cetuximab Monoclonal antibody Intravenous